European Companies Search Engine
EU funding (€3,605,245): COmbatting disorders of adaptive immunity with Systems MedICine Hor10 Oct 2017 EU Research and Innovation programme "Horizon"
Text
COmbatting disorders of adaptive immunity with Systems MedICine
Background: EU countries face large health challenges to combat chronic diseases. Recently, systems medicine has emerged as a promising discipline to accelerate the translation of basic research into applications for improved diagnostics and personalized treatment. Its power arises from the integration of laboratory and computational approaches crossing research disciplines and sectors to solve clinical questions. COSMIC delivers the next generation of leading, entrepreneurial, and innovative systems medicine professionals having expertise, skills, and experience to successfully combat complex human disorders. These professional will find excellent career opportunities. COSMIC focuses on B-cell neoplasia and rheumatoid arthritis, prototypical diseases originating from abnormal functioning of immune cells, often resulting in similar antigen specificities. COSMIC enables Early Stage Researchers to play a leading role in this exciting field. Approach: COSMIC develops and integrate experimental and computational approaches and establish a unique cross-fertilization between oncology and auto-immunity. In addition to transferable skills, the training program focuses on establishing a double expertise in laboratory and computational to address clinical questions. It involves a wide-range of stakeholders: (pre)clinical departments, companies, patient groups, students, and the general public. COSMIC will establish a link with the leading European EASyM and ISBE initiatives, and aims to harmonize systems medicine training throughout Europe by connecting to other EU (Marie Curie systems medicine) training initiatives. Impact: COSMIC (i) significantly improves ESR career perspectives (ii) leads to new public-private collaborations increasing competitiveness for companies; (iii) contributes to future oncology and immunology medical care; (iv) contributes to the EU systems medicine best practices.
Funded Companies:
| Company name | Funding amount |
| ? | |
| €766,123 | |
| €0.00 | |
| Anaxomics Biotech SL | €247,873 |
| €242,387 | |
| HELMHOLTZ-ZENTRUM für INFEKTIONSFORSCHUNG GmbH | €498,433 |
| IBM RESEARCH GmbH | €265,227 |
| €258,061 | |
| Institut National de Recherche en Informatique et Automatique | €262,876 |
| Karolinska Institutet | €527,319 |
| Redoxis AB | €263,659 |
| €273,288 |
Source: https://cordis.europa.eu/project/id/765158
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Biotecture, Amsterdam, Netherlands.
The visualizations for "Biotecture - EU funding (€3,605,245): COmbatting disorders of adaptive immunity with Systems MedICine"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
